Brad Loncar

JPMorgan Chase & Co. (NYSE: JPM) is taking heat from investors, reporters and biotech enthusiasts this week after the company decided to restrict access to its small breakout sessions following presentations at its upcoming 36th Annual Healthcare Conference in San Francisco Jan. 8-11. “...

Last year, a new crop of biotechnology exchanged-traded funds brought refined, laser-like focus to the fast-growing market segment. Biotech ETFs making their debuts in late 2014 included funds devoted exclusively to companies with products in specific stages of clinical trials or only to those...